24/7 Market News Snapshot 11 July, 2025 – Cel-Sci Corporation (NYSE:CVM)
DENVER, Colo., 11 July, 2025 (www.247marketnews.com) – (NYSE:CVM) are discussed in this article.
Cel-Sci Corporation, a leader in cancer immunotherapy, today reported a notable opening on the NYSE American at $6.26, although the stock experienced a significant decline of 8.56%, dropping to a current price of $3.493. The day’s trading witnessed a robust volume of 27 million shares, suggesting heightened investor engagement, potentially influenced by market sentiment or recent company developments. Investors are advised to monitor critical support levels around $3.00, while resistance may be identified near the previous opening price. The volatility in the stock emphasizes the importance of careful assessment of trading trends and market conditions when considering investment decisions regarding Cel-Sci.
In a strategic move to bolster its financial position, Cel-Sci announced a successful pricing for a best-efforts offering of 1,500,000 shares of its common stock at $3.82 per share. This transaction, expected to close on July 14, 2025, is projected to yield gross proceeds around $5.7 million before accounting for placement agent fees and expenses. The funds raised will primarily support the ongoing development of Multikine, an innovative cancer treatment designed to enhance the immune response against tumors. Additionally, these proceeds will contribute to general corporate purposes and working capital.
Multikine is notable for its unique approach in targeting a patient’s immune system prior to standard treatments like surgery or chemotherapy. To date, it has been administered to over 740 patients and has received Orphan Drug designation from the FDA for its application in neoadjuvant therapy for squamous cell carcinoma of the head and neck. As the sole placement agent for this offering, ThinkEquity will facilitate the transaction, with further details available through the official U.S. Securities and Exchange Commission (SEC) channels. This offering exemplifies Cel-Sci’s commitment to advancing therapies that could enhance cancer treatment outcomes.